Načítá se...
Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need fo...
Uloženo v:
| Vydáno v: | Am J Bioeth |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699477/ https://ncbi.nlm.nih.gov/pubmed/26632357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15265161.2015.1104160 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|